CJC-1295 (Research Overview)
CJC-1295 with DAC is a modified GHRH(1-29) analog incorporating Drug Affinity Complex (DAC) technology for extended half-life. It has been studied for its ability to produce sustained growth hormone pulse stimulation and elevated IGF-1 levels.
Mechanism of Action
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically the first 29 amino acids of the native sequence with modifications to improve stability and receptor binding. The DAC (Drug Affinity Complex) modification enables covalent binding to serum albumin, dramatically extending the compound's half-life from minutes (native GHRH) to approximately 6–8 days.
By binding to GHRH receptors on somatotroph cells in the anterior pituitary, CJC-1295 stimulates growth hormone secretion. Unlike exogenous GH administration, GHRH analogs preserve the pulsatile pattern of GH release, which researchers consider important for maintaining physiological GH signaling dynamics.
Research Areas
Clinical research has examined CJC-1295's effects on GH and IGF-1 levels in healthy adult subjects. Published data have demonstrated dose-dependent increases in mean GH concentrations and sustained IGF-1 elevation over multi-week observation periods. The extended half-life enabled by DAC technology has been a key pharmacological feature studied in these trials.
Body composition research has investigated the relationship between CJC-1295-induced GH/IGF-1 elevation and changes in lean mass, fat mass, and bone mineral density. GH axis research more broadly has examined CJC-1295 as a tool for studying somatotroph function and GH secretory dynamics in aging populations.
CJC-1295 is frequently studied in combination with ghrelin receptor agonists such as Ipamorelin, as the two compounds stimulate GH release through distinct but complementary receptor pathways. This combination approach has been a common design in GH axis research protocols. All research referenced here was conducted in controlled laboratory or clinical settings. CJC-1295 w/ DAC is supplied by Sealed Peptides strictly for research use only (RUO).
Specification summary
CJC-1295 w/ DAC 5mg
Stated purity ≥99%. For laboratory research use only.
Related materials
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683 · DOI
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. PMID 15817669 · DOI
- Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;26(3):343-352. PMID 39934495 · DOI
- Bertherat J, Bluet-Pajot MT, Epelbaum J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol. 1995;132(1):12-24. PMID 7850005 · DOI
Cited literature is provided for scientific context only and does not describe or endorse any use of these products.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.